ClinicalTrials.gg
RecruitingNCT04893109Updated Aug 19, 2026

ATEMPT 2.0: Adjuvant T-DM1 vs TH

A Phase 2 interventional study of trastuzumab-emtansine and Trastuzumab SC in Breast Cancer and HER2-positive Breast Cancer, sponsored by Dana-Farber Cancer Institute. Recruiting at 53 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms — 11 open to participants now, 16 under way, 2 of them phase 3. Ado-Trastuzumab Emtansine · Breast Neoplasms.

Planned enrollment
10th of 56
500 · median 103
Started
2021
with 3 others
Phase 2
26 of 56
9 open now
Primary completion
2028-11
later than 11 of 15 live
Registered
45th of 56
by date
Lead sponsor
6 of 56
Dana-Farber Cancer Institute

Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, this one is the 10th largest by planned enrollment, is one of 4 that started in 2021, is one of 26 in phase 2, reaches primary completion later than 11 of the 15 other live ones, and was the 45th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About Ado-Trastuzumab Emtansine

Ado-Trastuzumab Emtansine: first FDA approval 2013 (KADCYLA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, or all of them as a file.
02

Study summary

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery.

The name of the study drugs involved are:

  • Trastuzumab-emtansine (T-DM1, Kadcyla)
  • Trastuzumab SC (Herceptin Hylecta)
  • Paclitaxel
Read the detailed description

This is a randomized phase II adjuvant study for women and men with Stage I HER2-positive invasive breast cancer. Participants will be randomized into one of two treatment arms in this study and receive:

  • Arm 1: trastuzumab-emtansine (T-DM1, Kadcyla) and trastuzumab SC (Herceptin Hylecta)
  • Arm 2: paclitaxel and trastuzumab SC (Herceptin Hylecta) This research study is looking to see if the study drug T-DM1 followed by trastuzumab SC will have less side-effects than traditional HER2-positive breast cancer treatment of trastuzumab and paclitaxel.The study is also looking to learn about the long-term benefits and disease-free survival of participants who are treated with T-DM1 followed by trastuzumab SC.

T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy. More specifically, the trastuzumab in T-DM1 first binds to the HER2 protein on the surface of the breast cancer cells and the DM1 then enters the cells and can cause them to die, preventing tumor growth. The FDA (the U.S. Food and Drug Administration) has not approved T-DM1 for use on its own in patients with stage I, II, or III breast cancer. However, it has been approved for use in (a) advanced or metastatic, previously treated breast cancer and (b) in some patients receiving postoperative treatment after preoperative chemotherapy and surgery have been completed.

Trastuzumab SC is a subcutaneous form of trastuzumab.Trastuzumab is a monoclonal antibody, which are disease-fighting proteins made by cloned immune cells. Paclitaxel and trastuzumab are considered a standard-of-care regimen in early breast cancer. Trastuzumab is FDA-approved to be administered as an IV (intravenous) or subcutaneous (muscular injection).

The research study procedures include screening for eligibility and study treatment including laboratory evaluations and follow up visits.

Participants will receive study treatment for a year in total and will be followed for 5 years after treatment.

It is expected that about 500 people will take part in this research study.

Genentech is supporting this research study by providing funding for the study and supplying trastuzumab-emtansine (T-DM1) and trastuzumab SC (subcutaneous).

03

Conditions studied

  • Breast Cancer
  • HER2-positive Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • HER2-positive Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have -positive Stage I confirmed invasive carcinoma of the breast. Patients must have node-negative (N0) or micrometastases (N1mic) breast cancer according to the AJCC 8th edition anatomic staging table.

    • If the patient has had a negative sentinel node , then no further axillary dissection is required, and the patient is determined to be node-negative. If an axillary dissection without sentinel lymph node biopsy is performed to determine nodal status, at least six axillary lymph nodes must be removed and analyzed, and determined to be negative, for the patient to be considered node-negative. Axillary nodes with single cells or tumor clusters ≤ 0.2 mm by either H\&E or immunohistochemistry (IHC) will be considered node-negative.
    • Any axillary lymph node with tumor clusters between 0.02 and 0.2 cm is considered a micrometastasis. Patients with a micrometastasis are eligible. An axillary dissection is not required to be performed in patients with a micrometastasis found by sentinel node evaluation. In cases where the specific pathologic size of lymph node involvement is subject to interpretation, the principal investigator will make the final determination as to eligibility. The investigator must document approval in the patient medical record.
    • Patients who have an area of a T1aN0, ER+ (defined as >10%), HER2-negative cancer in addition to their primary HER2-positive tumor are eligible.
  • HER2-positive by ASCO CAP 2018 guidelines, confirmed by central testing. NOTE: HER-2 status must be confirmed to be positive by central review by NeoGenomics prior to patient starting protocol therapy. Patients previously having had HER2 immunohistochemical testing by NeoGenomics do not need to undergo retesting for central confirmation of HER2 status.

NOTE: DCIS components will not be counted in the determination of HER2 status

  • ER/PR determination is required. ER and PR assays should be performed by immunohistochemical methods according to the local institution standard protocol.
  • Bilateral breast cancers that individually meet eligibility criteria are allowed.
  • Patients with multifocal or multicentric disease are eligible, as long as each tumor individually meets eligibility criteria. Central confirmation is needed for any site of disease that is tested to be HER2-positive by local testing (unless testing was previously done by NeoGenomics).
  • Patients with a history of ipsilateral DCIS are eligible if they were treated with wide excision alone, without radiation therapy, or treated with a mastectomy for this current breast cancer. Patients with a history of contralateral DCIS are not eligible.
  • ≤ 90 days between the planned treatment start date and the patient's most recent breast surgery for this breast cancer
  • ≥ 18 years of age with any menopausal status.
  • Performance Status 0 or 1
  • All tumor should be removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy), with either a sentinel node biopsy or axillary dissection

    • All margins should be clear of invasive cancer or DCIS (i.e. no tumor on ink). The local pathologist must document negative margins of resection in the pathology report. If all other margins are clear, a positive posterior (deep) margin is permitted, provided the surgeon documents that the excision was performed down to the pectoral fascia and all tumor has been removed. Likewise, if all other margins are clear, a positive anterior (superficial; abutting skin) margin is permitted provided the surgeon documents that all tumor has been removed.
  • Patients undergoing breast conservation therapy (i.e. lumpectomy) must not have any to radiation therapy. Radiation to the conserved breast is required.
  • Patients may have received up to 4 weeks of tamoxifen therapy, or other hormonal therapy, for therapy for this cancer. Patients cannot receive adjuvant hormonal therapy during protocol treatment for the first 12 weeks.
  • Prior oophorectomy for cancer prevention is allowed.
  • Patients who have undergone partial breast radiation (duration ≤ 14 days) prior to registration are eligible. Partial breast radiation must be completed prior to 2 weeks before starting protocol therapy. Patients who have undergone whole breast radiation are not eligible.
  • Patients who have participated in a window study (treatment with an agent prior to surgery for ≤ 2 weeks) are eligible. Patients must have discontinued the investigational agent at least 14 days before participation.
  • Adequate bone marrow function:

    • ≥ 1000/mm3,
    • ≥ 9 g/dl
    • ≥ 100,000/mm3
  • Adequate hepatic function:

    • Total ≤ 1.2mg/dL
    • and ALT ≤ 1.5x Institutional
    • For patients with Gilbert syndrome, the direct bilirubin should be within the institutional normal range. Serum alkaline phosphatase should be ≤ 1.5x Institutional ULN.
  • (LVEF) ≥ 50%
  • Premenopausal patients must have a negative serum or urine pregnancy test, including women who have had a tubal ligation and for women less than 12 months after the onset of menopause.
  • Women of and men with partners of childbearing potential must be willing to use one highly effective form of nonhormonal or two effective forms of nonhormonal contraception by the patient and/or partner. Contraceptive use must be continued for the duration of the study treatment and for 7 months after the last dose of study treatment. Hormonal birth control methods are not permitted.
  • Patients should have tumor tissue available, and a tissue block of sufficient size to make 15 slides, which must be sent to DFCI for correlative research. If a tissue block is unavailable, sites may send one H\&E-stained slide and 15 unstained sections of paraffin-embedded tissue on uncharged slides. Slide sections should be 4-5 microns in thickness. It is also acceptable to submit 2 cores from a block of invasive tissue using a 1.2 mm diameter coring tool. If tumor is not available, the investigator must document why tissue is not available in the patient medical record, and that efforts have been made to obtain tissue.
  • Willing and able to sign
  • Must be able to read and understand English in order to participate in the quality of life surveys. If patient does not read and understand English, the patient is still eligible, but cannot participate in the quality of life surveys.

Exclusion criteria

Exclusion Criteria:

  • Any of the following due to teratogenic potential of the study drugs:

    • Pregnant women
    • Nursing women
    • Women of who are unwilling to employ adequate (condoms, diaphragms, IUDs, surgical sterilization, abstinence, etc.).
    • Men who are unwilling to employ adequate contraception (condoms, surgical sterilization, abstinence, etc.).
  • Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes (diffuse brawny cutaneous induration with an erysipeloid edge)
  • Patients with a history of previous invasive breast cancer.
  • History of prior chemotherapy in the past 5 years.
  • History of paclitaxel therapy
  • Patients with active liver disease, for example due to virus, virus, hepatic disorder, or sclerosing cholangitis
  • Individuals with a history of a different are ineligible except for the following circumstances:

    • Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy.
    • Individuals with the following cancer are eligible regardless of when they were diagnosed and treated: cervical cancer in situ, and non-melanoma cancer of the skin.
  • Intercurrent illness including, but not limited to: ongoing or active, unresolved systemic infection, renal failure requiring dialysis, active cardiac disease, prior myocardial infarction (asymptomatic changes on suggestive of old MI is not an exclusion), history of CHF, current use of any therapy specifically for CHF, uncontrolled hypertension, significant psychiatric illness, or other conditions that in the opinion of the investigator limit compliance with study requirements.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Arm A. T-DM1 followed by Trastuzumab SC

    Randomized participants will receive intravenous T-DM1 every 3 weeks for 6 cycles (18 weeks) and then Trastuzumab SC (subcutaneous) every 3 weeks for 11 cycles

    Drug: trastuzumab-emtansine · Drug: Trastuzumab SC

  • Experimental
    Arm B: Paclitaxel with Trastuzumab SC, followed by Trastuzumab SC alone

    Randomized participants will receive weekly intravenous Paclitaxel for 12 weeks (4 cycles) and Trastuzumab SC (subcutaneous) every 3 weeks for 17 cycles. The first 4 doses Trastuzumab SC are given with Paclitaxel.

    Drug: Trastuzumab SC · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of clinically relevant toxicities (CRT)

    Compare the incidence of clinically relevant toxicities (CRT) in patients with Stage I HER2-positive breast cancer treated with trastuzumab emtansine followed by trastuzumab SC to the incidence in those treated with paclitaxel in combination with trastuzumab SC as assessed by PRO-CTCAE

    Time frame: First 18 weeks of treatment

  2. Disease Free Survival (DFS)

    Evaluate disease-free survival in the T-DM1 followed by trastuzumab SC arm

    Time frame: Time from randomization to first Disease Free Survival (DFS) event up to 72 months

Secondary outcomes

  1. Grade 3 and 4 adverse events

    Compare the incidence of all grade 3 and 4 adverse events in patients treated with adjuvant trastuzumab emtansine followed by trastuzumab SC to the incidence in those receiving paclitaxel in combination with trastuzumab SC

    Time frame: Enrollment to end of treatment up to 1 year

  2. Quality of Life Assessment: FACT B

    Compare responses to FACT-B quality of life (QOL) questionnaire in patients receiving trastuzumab emtansine followed by trastuzumab SC to that experienced by patients receiving paclitaxel in combination with trastuzumab SC.

    Time frame: Enrollment to end of treatment up to 1 year

  3. Symptoms related to therapy

    Evaluate symptoms related to therapy in patients receiving trastuzumab emtansine followed by trastuzumab SC compared to those receiving paclitaxel in combination with trastuzumab SC using the Rotterdam Symptom Checklist (RSCL)

    Time frame: Enrollment to end of treatment up to 1 year

  4. Symptoms related to therapy

    Evaluate symptoms related to therapy in patients receiving trastuzumab emtansine followed by trastuzumab SC compared to those receiving paclitaxel in combination with trastuzumab SC using the Patient Neurotoxicity Questionnaire (PNQ)

    Time frame: Enrollment to end of treatment up to 1 year

  5. Effects of therapy on work productivity

    Evaluate effects of therapy on work productivity and activity using the Work Productivity and Activity Impairment Questionnaire (WPAI-SHP) in patients receiving trastuzumab emtansine followed by trastuzumab SC compared to those receiving paclitaxel in combination with trastuzumab SC

    Time frame: Enrollment to end of treatment up to 1 year

  6. Effect of alopecia on patients

    Evaluate the effects of alopecia on patients receiving paclitaxel in combination with trastuzumab SC using an alopecia questionnaire

    Time frame: Enrollment to end of treatment up to 1 year

  7. Incidence of Side Effects

    Compare incidence of sensory neuropathy, headache, arthralgia and myalgia using PRO-CTCAE criteria in patients receiving trastuzumab emtansine followed by trastuzumab SC to that experienced by patients receiving paclitaxel in combination with trastuzumab SC

    Time frame: Enrollment to end of treatment up to 1 year

  8. Incidence of grade 3-4 cardiac left ventricular dysfunction

    Evaluate the incidence of grade 3-4 cardiac left ventricular dysfunction in patients treated with adjuvant trastuzumab emtansine followed by trastuzumab SC compared to those receiving paclitaxel with trastuzumab SC

    Time frame: Enrollment to end of treatment up to 1 year

  9. Incidence of trastuzumab-emtansine-induced grade 2-4 thrombocytopenia

    Evaluate the incidence of trastuzumab-emtansine-induced grade 2-4 thrombocytopenia

    Time frame: Enrollment to end of treatment up to 1 year

  10. Percentage of patients with amenorrhea

    Investigate the percentage of patients with amenorrhea at various time points after the start of treatment in premenopausal women receiving treatment with trastuzumab emtansine followed by trastuzumab SC and paclitaxel with trastuzumab SC

    Time frame: Enrollment to end of treatment up to 1 year

  11. Evaluation of gene predictors of trastuzumab-emtansine-induced grade 2-4

    Evaluate gene biomarkers predictive of trastuzumab-emtansine-induced grade 2-4 thrombocytopenia

    Time frame: Enrollment to end of treatment up to 1 year

  12. Gene Profiling

    Utilize genomic profiling to query a large panel of cancer gene mutations and gene expression in patients with Stage I HER2-positive breast cancer

    Time frame: Enrollment to end of treatment up to 1 year

  13. Radiation therapy Toxicity

    Evaluate the incidence of toxicities attributed to radiation therapy when given concurrently with trastuzumab SC after receipt of either trastuzumab emtansine or paclitaxel

    Time frame: Enrollment to end of treatment up to 1 year

  14. Overall survival

    Describe overall survival in patients with Stage I HER2-positive breast cancer treated with trastuzumab emtansine followed by trastuzumab SC

    Time frame: Enrollment to end of treatment up to 1 year

07

Study locations

46 of 53 sites recruiting
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158, United States
    Recruiting
    • Hope Rugo, MD · Contact
    • Hope Rugo, MD · Principal investigator
  • Smilow Cancer Hospital Care center at Derby
    Derby, Connecticut 06418, United States
    Recruiting
    • Clinical Trial Offcie Yale Cancer Center · Contact(203) 734-1664
    • Daniel O'Neil, MD · Principal investigator
  • Smilow Cancer Hospital Care center at Fairfield
    Fairfield, Connecticut 06824, United States
    Recruiting
    • Clinical Trials Office Yale Cancer Center · Contact(203) 255-2766
    • Daniel O'NEIL, MD · Principal investigator
  • Smilow Cancer Hospital Care center at Glastonbury
    Glastonbury, Connecticut 06033, United States
    Recruiting
    • Clinical Trial Office Yale Cancer Center · Contact(860) 714-9170
    • Daniel O'Neil, MD · Principal investigator
  • Smilow Cancer Hospital Care center at Greenwich
    Greenwich, Connecticut 06830, United States
    Recruiting
    • Clinical Trials Office Yale Cancer Center · Contact(203) 863-3700
    • Daniel O'Neil, MD · Principal investigator
  • Smilow Cancer Hospital Care center at Guilford
    Guilford, Connecticut 06437, United States
    Recruiting
    • Clinical Trial Office Yale Cancer Center · Contact(203) 453-9192
    • Daniel O'Neil, MD · Principal investigator
  • Smilow Cancer Hospital Care center at St. Francis
    Hartford, Connecticut 06105, United States
    Recruiting
    • Clinical Trial Office Yale Cancer Center · Contact(860) 714-4680
    • Daniel O'Neil, MD · Principal investigator
  • Smilow Cancer Hospital Care center at Long Ridge
    Long Ridge, Connecticut 06902, United States
    Recruiting
    • Clinical Trial Office Yale Center · Contact(203) 863-3700
    • Daniel O'Neil, MD · Principal investigator
  • Yale Cancer Center at Yale University School of Medicine
    New Haven, Connecticut 06520-8028, United States
    Recruiting
    • Clinical Trial Office Clinical Trials Office - Yale Cancer Center · Contact203-785-5702
    • Daniel O'Niel, MD · Principal investigator
  • Smilow Cancer Hospital Care center at North Haven
    North Haven, Connecticut 06510, United States
    Recruiting
    • Clinical Trials Office Yale Cancer Center · Contact(203) 407-8002
    • Daniel O'neil, MD · Principal investigator
  • Stamford Hospital
    Stamford, Connecticut 06904, United States
    Recruiting
    • K.M. Steve Lo, MD · Contactslo@stamhealth.org
    • K. M. Steve Lo, MD · Principal investigator
  • Smilow Cancer Hospital Care center at Torrington
    Torrington, Connecticut 06790, United States
    Recruiting
    • Clinical Trial Office Yale Cancer Center · Contact(860) 482-5384
    • Daniel O'Neil, MD · Principal investigator
  • Smilow Cancer Hospital Care center at Trumbull
    Trumbull, Connecticut 06611, United States
    Recruiting
    • Clinical Trials Office Cancer Trial · Contact(203) 502-8400
    • Daniel O'Neil, MD · Principal investigator
  • Smilow Cancer Hospital Care center at Waterbury
    Waterbury, Connecticut 06708, United States
    Recruiting
    • Clinical Trials Office Yale Cancer Center · Contact(203) 755-6311
    • Daniel O'Neil, MD · Principal investigator
  • Smilow Cancer Hospital Care center at Waterford
    Waterford, Connecticut 06385, United States
    Recruiting
    • Clinical Trials Office Yale Cancer Center · Contact(860) 444-3744
    • Daniel O'Neil, MD · Principal investigator
  • Miami Cancer Institute/Baptist Hospital of Miami
    Miami, Florida 33176, United States
    Recruiting
    • Reshma Mahtani, DO · Contact
    • Reshma Mahtani, DO · Sub investigator
  • Miami Cancer Institute - Plantation (MCIP)
    Plantation, Florida 33324, United States
    Recruiting
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
    • Susan Cohn, MD · Contact773-702-2571
    • Nan Chen, MD · Principal investigator
  • Indiana University Health Joe & Shelly Schwarz Cancer Center
    Carmel, Indiana 46032, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • IU Health North Hospital
    Carmel, Indiana 46032, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
    Indianapolis, Indiana 46202, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Indiana University Sidney and Lois Eskenazi Hospital
    Indianapolis, Indiana 46202, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Eastern Maine Medical Center (Northern Light)
    Brewer, Maine 04412, United States
    Recruiting
  • New England Cancer Specialists
    Scarborough, Maine 04074, United States
    Recruiting
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02215, United States
    Recruiting
    • Laura Spring, MD · ContactLspring2@partners.org · 617-724-4000
    • Laura Spring, MD · Principal investigator
  • Dana-Farber at St. Elizabeth's Medical Center
    Brighton, Massachusetts 02135, United States
    Recruiting
  • Lahey Clinic
    Burlington, Massachusetts 01805, United States
    Recruiting
  • Mass General North Shore Cancer Center
    Danvers, Massachusetts 01923, United States
    Recruiting
  • Dana-Farber Brigham Cancer Center - Foxborough
    Foxborough, Massachusetts 02035, United States
    Recruiting
    • Natalie Sinclair · Contactnsinclair1@partners.org · 781-624-4800
    • Natalie Sinclair, MD · Principal investigator
  • Dana-Farber Cancer Instiute - Merrimack Valley
    Methuen, Massachusetts 01844, United States
    Recruiting
  • Dana-Farber at Milford
    Milford, Massachusetts 01757, United States
    Recruiting
  • Newton Wellesley Hospital
    Newton, Massachusetts 02462, United States
    Recruiting
  • Berkshire Medical Center
    Pittsfield, Massachusetts 01201, United States
    Recruiting
    • Lori O'Brien · Contactlobrien@bhs1.org
    • Thomas Fynan, MD · Principal investigator
  • Dana Farber at South Shore Hospital
    Weymouth, Massachusetts 02190, United States
    Recruiting
  • NH Oncology-Hematology, PA - Payson Center for Cancer Care
    Concord, New Hampshire 03301, United States
    Recruiting
    • Ali Fleury · Contacta.fleury@nhoh.com · 6032242556
    • Douglas Weckstein, MD · Principal investigator
  • Dana-Farber Cancer Insitute at Londonderry Hospital
    Londonderry, New Hampshire 03053, United States
    Recruiting
  • Solinsky Center for Cancer Care (NH Oncology-Hematology, PA)
    Manchester, New Hampshire 03103, United States
    Recruiting
    • Ali Fleury · Contacta.fleury@nhoh.com · 6032242556
    • Douglas Weckstein, MD · Principal investigator
  • New England Cancer Specialists - Portsmouth
    Portsmouth, New Hampshire 03801, United States
    Recruiting
  • New York University Langone Hospital -Brooklyn
    Brooklyn, New York 11220, United States
    Recruiting
    • Breast Cancer Center · Contact(718) 630-7000
    • Nina D'Abreo, MD · Principal investigator
  • New York University Langone Hospital - Long Island
    Mineola, New York 11501, United States
    Recruiting
  • New York University Langone Health
    New York, New York 10016, United States
    Recruiting
  • Northwell University
    New York, New York 10075, United States
    Recruiting
    • Francisco Esteva · Contactfesteva@northwell.edu · (855)-273-2789
    • Francisco Esteva · Principal investigator
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Duke Women's Cancer Care Raleigh
    Raleigh, North Carolina 27710, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Stefanie Spielman Comprehensive Breast Center
    Columbus, Ohio 43212, United States
    Recruiting
    • Breast Cancer Clinical Trials · Contact800-293-5066
    • Gilbert Bader, MD · Principal investigator
  • University of Pennsylvania, Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • University of Pittsburgh Medical Center Cancer UPMC- Magee Women's Hospital
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
  • Smilow Cancer Hospital Care center at Westerly
    Westerly, Rhode Island 02891, United States
    Recruiting
    • Clinical Trials Office Yale Cancer Center · Contact(401) 656-4950
    • Daniel O'Neil, MD · Principal investigator
  • Greco-Hainsworth Centers for Research/Tennessee Oncology
    Nashville, Tennessee 37203, United States
    Recruiting
    • PJ Patterson · Contactppatterson@tnonc.com · 629-294-0801
    • Sara Nunnery, MD · Principal investigator
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Vicente Valero, MD · Contactvvalero@mdanderson.org · 713 563 0751
    • Vicente Valero, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Nov 2028, 88 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 88 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2021
First posted
May 19, 2021
StartActual
Jun 16, 2021
Primary completionEst.
Nov 1, 2028
CompletionEst.
May 1, 2029
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04893109
Collaborators
Genentech, Inc.
Responsible party
Sara Tolaney, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
May 19, 2021
Start date
Jun 16, 2021
Primary completion
Nov 1, 2028 (estimated)
Completion
May 1, 2029 (estimated)
Last update
Aug 19, 2026

Study contacts

Sara Tolaney, MD, MPH
Contact
sara_tolaney@dfci.harvard.edu
617-632-2335
Sara Tolaney, MD, MPH
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ado-Trastuzumab Emtansine · Trastuzumab · Paclitaxel

Start the discussion